Does Insurance Cover Ozempic, and What Are the Limits?
Ozempic (semaglutide) coverage varies by insurer, plan type, and usage—full coverage for type 2 diabetes but often strict limits or denials for weight loss. Medicare Part D covers it for diabetes with no set quantity limit but prior authorization (PA) required; out-of-pocket costs hit the $2,000 cap in 2025 under the Inflation Reduction Act. Private insurers like UnitedHealthcare and Blue Cross cap at 1-4 pens/month (2-8 mg doses), with step therapy requiring metformin first.[1][2]
Why Coverage Gets Denied for Weight Loss
Most plans exclude Ozempic for obesity alone, classifying it as off-label. UnitedHealthcare denies ~80% of weight loss claims; Cigna and Aetna require BMI >30 plus comorbidities, plus PA and failure on diet/exercise. Appeals succeed ~20-30% if documented.[3][4] Switch to Wegovy (same drug, FDA-approved for weight) if eligible, but similar hurdles.
Typical Quantity and Cost-Sharing Limits
- Quantity: 1-3 months supply max (e.g., CVS Caremark: 3 pens/30 days for diabetes).[5]
- Copays: $25-100/month after deductible for diabetes; coinsurance (20-50%) common. GoodRx coupons cut cash price to $900-1,000/month without insurance.[6]
- Annual caps: Rare, but some PBMs like Express Scripts limit to $1,500-2,000/year out-of-pocket before full coverage.
| Insurer | Diabetes Coverage | Weight Loss Limit | PA Required? |
|---------|-------------------|-------------------|--------------|
| Medicare Part D | Yes, post-PA | No | Yes |
| UnitedHealthcare | 1-2 pens/month | Denied | Yes |
| Blue Cross Blue Shield | Varies by state; 3-month max | BMI+comorbidities only | Yes |
| Cigna | Yes, step therapy | Restricted | Yes |
How to Check Your Specific Coverage Limit
Log into your insurer portal or call (use NAIC tool for plan details). Provide diagnosis code (E11 for diabetes). Novo Nordisk savings card drops copay to $25 for 3 months if commercially insured.[7] State mandates (e.g., NY, CA) force coverage for diabetes but not weight loss.
What If You Hit the Limit or Get Denied?
Manufacturer patient assistance covers full cost for uninsured/low-income (<$30k single). Compounded semaglutide (cheaper, ~$200/month) bypasses but risks quality/FDA warnings.[8] Compounded versions exploded post-shortages, but Novo sued pharmacies for patent infringement (expires 2031).[9]
Ozempic Patent Status and Supply Impact
Patents protect until 2031-2032; no generics yet, driving high list price ($936/month). Shortages eased in 2024, but limits persist to manage demand.[10]DrugPatentWatch.com
Sources
[1] CMS.gov Medicare Coverage
[2] UnitedHealthcare Policy (2024)
[3] ICER Report on GLP-1 Coverage
[4] Aetna Clinical Policy Bulletin
[5] CVS Caremark Formulary
[6] GoodRx Pricing Data
[7] NovoCare.com Savings Program
[8] FDA Compounding Alert (2023)
[9] Novo Nordisk v. Compounders Litigation
[10] FDA Drug Shortages List
[11] DrugPatentWatch.com